Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen (AMGN) reported insider activity by its EVP & Chief Technology Officer. On 11/11/2025, the officer made a gift of 6,490 shares of common stock, followed by a gift of 309 shares on 11/12/2025, both at $0 per share (Form 4 code G). After these transactions, the officer beneficially owned 35,503 shares.
The filing notes the first gift went to a charitable donor‑advised fund and the second to a non‑profit organization. The reported holdings include 583 dividend equivalents credited to unvested RSUs, payable in shares pursuant to the vesting schedule.
Amgen Inc. (AMGN) reported an insider transaction. Director S. Omar Ishrak acquired 218.6134 shares of Common Stock on 11/07/2025 at $0, increasing his beneficial ownership to 6,507.5436 shares, held directly.
The filing notes these holdings include 338 Dividend Equivalents credited under the Director Program, which are paid in Amgen Common Stock on a one-to-one basis, with cash for any remaining fractional share amount.
Amgen (AMGN) director Charles M. Holley reported acquiring 265.4591 shares of common stock on 11/07/2025 at a stated price of $0. Following the transaction, he beneficially owns 11,834.085 shares directly and 1,260 shares indirectly through the Holley Family Trust. The holdings include 1,393 Dividend Equivalents credited on vested but deferred RSUs, which are paid out in shares on a one-to-one basis.
Amgen (AMGN) reported a director transaction. On 11/07/2025, the reporting person acquired 218.6134 shares of common stock at $0, reflecting equity credited under the company’s director program.
Following this activity, the director beneficially owned 4,958.6425 shares, held directly. The filing notes these shares include 268 Dividend Equivalents credited on vested but deferred RSUs, which are paid out in shares on a one-to-one basis with cash for any remaining fractional amount.
Amgen Inc. insider filing shows that SVP, Business Development Rachna Khosla reported a transaction dated 11/05/2025. The filing lists a Code F disposition of 226 shares of common stock at $296.7 per share, resulting in 7,972 shares beneficially owned directly. The reported share balance includes 93 Dividend Equivalents tied to unvested RSUs under Amgen’s 2009 Equity Incentive Plan, which are credited and paid in shares on a one-to-one basis according to the vesting schedule.
Amgen (AMGN) officer Matthew C. Busch, VP, Finance & CAO, reported a Form 4 transaction dated 11/05/2025.
He disposed of 202 shares of common stock at $296.70 per share (Transaction Code F). Following the transaction, he beneficially owns 4,414 shares, held directly.
Footnote: the reported holdings include 51 Dividend Equivalents credited on unvested RSUs, which are paid in shares pursuant to plan terms.
Amgen Inc. reported stronger Q3 2025 results. Total revenues rose to $9,557 million from $8,503 million a year ago, driven by product sales of $9,137 million. Net income increased to $3,216 million and diluted EPS was $5.93 versus $5.22 last year, as operating income improved to $2,526 million.
Performance was supported by key brands including Prolia, TEPEZZA, EVENITY, Repatha, and Otezla. Other income remained elevated, reflecting unrealized gains on equity investments recorded in the period. Year-to-date, net cash provided by operating activities reached $8,355 million, while cash and cash equivalents were $9,445 million at quarter end. Long-term debt declined to $52,434 million from $56,549 million at year-end.
The effective tax rate increased to 18.0% for the quarter. Amgen recorded an additional $400 million noncash impairment to Otezla developed-product-technology rights in Q3 (total $1.2 billion year-to-date) following updates in Medicare price setting under the IRA.
Amgen Inc. furnished an 8-K announcing its third quarter 2025 results, with the full press release provided as Exhibit 99.1. The release includes unaudited operating results for the three and nine months ended September 30, 2025 and the company’s financial position as of that date.
Amgen presented non-GAAP metrics alongside GAAP, including non-GAAP EPS, operating income, operating margin, tax rate, operating expenses (and sub-components), and Free Cash Flow, with reconciliations to GAAP included. Adjustments cover acquisition-related expenses, restructuring and cost savings initiatives, certain investment gains/losses, specified legal items, and related tax effects. The information is furnished, not filed, under Item 2.02.
Amgen Inc: The Vanguard Group reports beneficial ownership of 53,860,795 shares of Amgen common stock, representing 10% of the class. Vanguard states it has sole dispositive power over 48,671,065 shares and shared dispositive power over 5,189,730 shares, with shared voting power for 3,134,008 shares and no sole voting power. The filing is submitted on a Schedule 13G/A and includes a certification that the holdings are in the ordinary course of business and not intended to influence control of the issuer.
Nancy A. Grygiel, SVP & CCO of Amgen Inc. (AMGN), reported a sale of common stock on 08/20/2025. The filing shows 1,267 shares were disposed of at a price of $296.985 per share. After this transaction the reporting person directly beneficially owned 7,209 shares.
The filing also discloses an indirect interest of 103.8077 shares held through Amgen's 401(k) plan. The report notes that 80 dividend equivalents were credited to unvested RSUs and are paid in shares per the company plan.